AI Article Synopsis

  • Patients with chronic myeloid leukemia (CML) who achieve a stable complete molecular response after being treated with dasatinib may maintain that response even after stopping the medication.
  • The study reports on three patients previously resistant to imatinib who had stable responses on dasatinib, with two maintaining their complete molecular response more than 12 months after discontinuation.
  • The presence of detectable leukemic DNA indicates that while some T-cell responses were observed, the underlying disease characteristics may resemble those achieved with imatinib, suggesting potential similarities in treatment outcomes.

Article Abstract

Patients with chronic myeloid leukemia, treated with imatinib, who have a durable complete molecular response, might remain in complete molecular response after stopping treatment. Previous reports of patients stopping treatment in complete molecular response have included only patients with a good response to imatinib. We describe 3 patients with stable complete molecular response on dasatinib treatment following imatinib failure. Two of the 3 patients remain in complete molecular response more than 12 months after stopping dasatinib. In these 2 patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to show that the leukemic clone remains detectable, as we have previously shown in imatinib-treated patients. Dasatinib-associated immunological phenomena, such as the emergence of clonal T-cell populations, were observed both in one patient who relapsed and in one patient in remission. Our results suggest that the characteristics of complete molecular response on dasatinib treatment may be similar to that achieved with imatinib, at least in patients with adverse disease features.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208693PMC
http://dx.doi.org/10.3324/haematol.2011.048165DOI Listing

Publication Analysis

Top Keywords

complete molecular
28
molecular response
24
durable complete
8
chronic myeloid
8
myeloid leukemia
8
adverse disease
8
disease features
8
patients
8
remain complete
8
stopping treatment
8

Similar Publications

MYCN-amplified spinal ependymomas: a rare aggressive subtype. Illustrative cases.

J Neurosurg Case Lessons

January 2025

Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Background: Spinal ependymomas are typically slow-growing tumors with a favorable prognosis. Recently, a new aggressive subtype has emerged with its own distinct histopathological and molecular features characterized by MYCN amplification. However, this subtype of spinal ependymoma is rare, and studies on its imaging characteristics are limited.

View Article and Find Full Text PDF

Thickness Dependent Structural Transition in Ph-BTBT-10 Thin Films and Stabilization of the Ubiquitous Interface Bilayer.

ACS Appl Mater Interfaces

January 2025

Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), Campus UAB, Carrer dels Til·lers, s/n, Bellaterra, 08193 Barcelona, Spain.

The influence of the film/substrate interface and the role of film thickness on the structural transition temperature for thin films of the asymmetric BTBT derivative 7-decyl-2-phenyl[1]benzothieno[3,2-][1]-benzothiophene (Ph-BTBT-10) have been addressed by using Kelvin probe force microscopy (KPFM) and synchrotron grazing incidence wide angle X-ray scattering (GIWAXS). Our data strongly suggest that the structural transformation from a single-layer phase to the thermodynamically stable bilayer structure develops from the bottom of the film to its surface. Contrary to observations in other organic semiconductor films, notably, the thinner the Ph-BTBT-10 film, the lower is the transition temperature.

View Article and Find Full Text PDF

Malian field isolates provide insight into Plasmodium malariae intra-erythrocytic development and invasion.

PLoS Negl Trop Dis

January 2025

Malaria Research and Training Center (MRTC), Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.

Plasmodium malariae is the third most prevalent human malaria parasite species and contributes significantly to morbidity. Nevertheless, our comprehension of this parasite's biology remains limited, primarily due to its frequent co-infections with other species and the lack of a continuous in vitro culture system. To effectively combat and eliminate this overlooked parasite, it is imperative to acquire a better understanding of this species.

View Article and Find Full Text PDF

Biological material and health information from patients are valuable for medical research. Under a "broad" consent model, hospital patients in Norway can consent to their biological material and health information being stored in research biobanks and used for "specific, broadly defined research purposes" within a specified medical research area but not for medical research in general. Patients are asked to provide new consent each time researchers wish to use their material in a different medical research area.

View Article and Find Full Text PDF

Traditionally, Bidens pilosa L. is an edible herb utilized for various ailments. The study accomplished a complete analysis of B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!